Last updated: August 19, 2026

An experimental personalized mRNA cancer vaccine developed jointly by Moderna and Merck has successfully met its primary goals in a landmark Phase 3 clinical trial for high-risk melanoma patients. The breakthrough therapy, named intismeran, combined with Merck’s established immunotherapy drug Keytruda, significantly extended the time patients lived without their cancer returning following surgical removal.

The Story at a Glance

The latest trial results mark the first successful late-stage evaluation of an mRNA-based therapeutic cancer vaccine. More than 1,100 patients with stage 2 to stage 4 melanoma participated in the study after undergoing surgery to remove detectable tumors. By training the immune system to recognize individual tumor mutations, the combination treatment reduced the risk of recurrence and prevented the cancer from spreading to distant parts of the body more effectively than Keytruda alone.

How the Story Developed

The collaboration between Moderna and Merck builds upon promising Phase 2 data presented earlier this year, which indicated that the personalized neoantigen vaccine lowered the risk of recurring melanoma by 49% and reduced distant spread or death by 59%. Following those signals, the companies pushed forward with the randomized Phase 3 study. Intismeran operates by analyzing a patient's specific tumor mutations, generating custom mRNA sequences, and teaching the immune system to target those distinct markers. This milestone brings both pharmaceutical firms significantly closer to filing for official regulatory approvals in the U.S.

Key People and Details

Financial markets reacted immediately to the announcement, with Moderna's stock surging over 120% to around $154.48 in morning trading, while Merck shares climbed more than 10% to $149.52. Key leaders involved in the research highlighted the broader implications for oncology. Professor Georgina Long, the study's principal investigator and chair of the University of Sydney's Melanoma Medical Oncology and Translational Research, called the findings a landmark moment for adjuvant treatment. Moderna CEO Stéphane Bancel and Merck Research Laboratories President Dr. Dean Y. Li emphasized that turning personalized mRNA therapies from an aspiration into clinical reality transforms the future of cancer care.

Reaction and Response

Medical experts and researchers across the globe have praised the trial data for validating a tailored treatment approach. Unlike traditional one-size-fits-all therapies, personalized vaccines target the unique genetic footprint of an individual's tumor. Analysts note that the successful trial also breathes new financial life into Moderna, which faced workforce reductions in 2025 following declining pandemic-era vaccine revenues. Regulatory discussions with agencies such as the U.S. Food and Drug Administration are expected to begin within the next few months.

What to Watch

With melanoma results secured, researchers are expanding trials into other difficult-to-treat malignancies. Moderna and Merck are currently evaluating intismeran in ongoing studies for non-small cell lung cancer, bladder cancer, renal cell carcinoma, and pancreatic cancer. Clinicians will be closely monitoring upcoming international medical meetings where detailed data sets from the Phase 3 melanoma trial are scheduled for full public presentation.

Frequently Asked Questions

• What is intismeran? Intismeran is an experimental personalized mRNA cancer vaccine designed to target unique mutations in a patient's tumor and train the immune system to fight the cancer.
• How does the vaccine work with Keytruda? While Keytruda helps unveil cancer cells so the immune system can attack them, intismeran teaches the immune system to recognize specific tumor markers, creating a dual-action defense mechanism.
• Who was included in the Phase 3 trial? The study evaluated more than 1,100 patients with stage 2 to stage 4 melanoma whose primary tumors had been completely removed through surgery.
• What are the next steps for approval? Executives from Merck and Moderna announced plans to initiate formal safety and regulatory discussions with agencies like the FDA in the coming months.
• Will this technology be tested on other cancers? Yes, clinical trials are already underway investigating the mRNA vaccine approach in lung, bladder, kidney, and other tumor types.